# VELCADE as Maintenance Treatment in Patients With Multiple Myeloma Following Autologous Peripheral Blood Stem Cell Transplantation (PBSCT)

> **NCT00311337** · PHASE2 · UNKNOWN · sponsor: **University of Wuerzburg** · enrollment: 61 (—)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** bortezomib

## Key facts

- **NCT ID:** NCT00311337
- **Lead sponsor:** University of Wuerzburg
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2005-10
- **Primary completion:** —
- **Final completion:** 2010-10
- **Target enrollment:** 61 (—)
- **Last updated:** 2006-04-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00311337

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00311337, "VELCADE as Maintenance Treatment in Patients With Multiple Myeloma Following Autologous Peripheral Blood Stem Cell Transplantation (PBSCT)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00311337. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*